review · Cureus
Artificial intelligence (AI) is being used by an increasing number of conversational agents, sometimes known as chatbots. In applications related to health care, such as those that educate and assist patients with chronic illnesses, which are among the main causes of mortality in the 21st century, they are becoming more and more common. Chatbots powered by AI allows for more frequent and efficient engagement with these patients. This systematic review aimed to examine the traits, medical conditions, and AI architectures of conversational agents that are based on artificial intelligence and are specifically made for chronic illnesses. We searched four databases (Scopus, Web of Science, PubMed, and Cumulative Index to Nursing and Allied Health Literature [CINAHL]) to search for relevant studies using specific inclusion and exclusion criteria. Among these databases, we found 386 studies that were screened for duplicates and then assessed by inclusion and exclusion criteria. We included the 10 most relevant studies in this systemic review. There is a dearth of research on AI-based interactive agents for chronic illnesses, and what little is available is primarily quasi-experimental studies, including chatbots in prototype stages that employ natural language processing (NLP) and enable multimodal user engagement. Future studies could benefit from comparing and evaluating AI-based conversational bots within and between various chronic health disorders using evidence-based methodology. In addition to improving comparability, more structured development and standardized evaluation procedures could improve the caliber of chatbots created for certain chronic diseases and their subsequent effects on the target patients.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.7759/cureus.81001
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.